阿比特龙-奥拉帕利联合疗法有助于治疗转移性去势抵抗性前列腺癌男性患者。
Abiraterone-Olaparib Combo Aids Men with mCRPC.
出版信息
Cancer Discov. 2018 Aug;8(8):OF4. doi: 10.1158/2159-8290.CD-NB2018-084. Epub 2018 Jun 28.
Abstract
Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status.
摘要
一项II期试验的最新研究结果表明，将抗雄激素药物阿比特龙与PARP抑制剂奥拉帕利联合使用，可显著提高转移性去势抵抗性前列腺癌患者的无进展生存期，无论其同源重组修复突变状态如何。
Zotero 插件